| Revenue growth | 23% YoY for full year FY26. |
|---|---|
| Margins | Gross margin healthy at 60%; EBITDA reached 29% in Q4. |
| Order book | Pretty much in place for next year. |
| Demand visibility | Strong momentum in CDMO and non-ARV generics. |
| Management confidence | High; confident in maintaining or improving EBITDA margins in FY27. |
Growth
FY26 Revenue grew 23% to ₹6,813 Cr; PAT surged 148% to ₹889 Cr; EBITDA margins expanded 6.7% to 26.8%.
Outlook
Guided ₹3,000 Cr capex over next 2 years; CDMO targeted to be 50% of revenue by FY30.
Risks
Geopolitical disruptions affecting raw material availability/logistics; solvent price volatility; increased debt for capex.
Earnings Call filed with NSE, NSE: LAURUSLABS. Summary written with AI assistance from the document.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,007.00
- Market cap
- ₹1,08,441 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 99.2×Sector 50.4×
- Promoter holding
- 27.47%-0.02% QoQ
- FII holding
- 28.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Laurus Labs Earnings Call Transcript: Key Takeaways
Laurus Labs delivered record quarterly revenue and EBITDA margins, driven by strong CDMO commercial supplies and recovery in the affordable medicine portfolio.
- Call
- Guides 50% growth
Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered a strong Q1 FY27 with ₹2,026 Cr revenue (up 29% YoY), driven by robust CDMO growth. EBITDA margins expanded to 31.8% due to favorable product mix and operational leverage.
Laurus Labs Q1 FY27 Results: Net Profit ₹362.1 Cr, Up 123.9% YoY
Laurus Labs Ltd reported revenue from operations of ₹2,026 Cr (+29.1% YoY) and net profit of ₹362.1 Cr (+123.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹362.1 Cr · +123.9% YoY
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered a robust 23% revenue growth in FY26, pivotally shifting its mix toward CDMO which now accounts for 30% of sales while maintaining ARV leadership.
Laurus Labs Earnings Call: Key Takeaways
Laurus Labs delivered record FY26 results with Revenue up 23% and Net Profit surging 148%, driven by a significant 36% jump in CDMO and improved operating leverage.